

References

I-120

1. Momtaz P, Postow MA. Immunologic checkpoints in cancer therapy: Focus on the programmed death-1 (PD-1) receptor pathway. *Pharmgenomics Pers Med*. 2014;7:357–365.
2. Forde P, Reiss K, Zeidan A, et al. What lies within: Novel strategies in immunotherapy for nonsmall cell lung cancer. *Oncologist*. 2013:1203-1213.
3. Opdivo® (nivolumab) [package insert]. Bristol-Myers Squibb Company, Princeton, NJ November 2018.
4. Keytruda® (pembrolizumab) [package insert]. Merck & Co., Inc., Whitehouse Station, NJ December 2018.
5. Robert C, Shachter J, Long G, et al. Pembrolizumab versus ipilimumab in advanced melanoma. *The New England Journal of Medicine*. 2015;DOI:10.1056/NEJMoa1503093.
6. Johnson DB, Peng C, Sosman JA. Nivolumab in melanoma: Latest evidence and clinical potential. *Therapeutic Advances in Medical Oncology*. 2015;7(2):97–106.
7. Ansell SM, Lesokhin AM, Borrello I, et al. PD-1 Blockade with Nivolumab in Relapsed or Refractory Hodgkin's Lymphoma. *The New England Journal of Medicine*. 2015;372(4):311-319.
8. Antonia SJ, Bendell JC, Taylor MH, et al. Lung Cancer—Non-Small Cell Local-Regional/Small Cell/Other Thoracic Cancers. *J Clin Oncol* 33, 2015 (suppl; abstr 7503).
9. Motzer RJ, Escudier B, McDermott DF, et al. Nivolumab versus Everolimus in Advanced Renal Cell Carcinoma. *N Engl J Med* 2015;373:1803-13.
10. Pembrolizumab. DrugPoints Summary. Micromedex 2.0. Truven Health Analytics, Inc. Greenwood Village, CO. Accessed 10/11/2016.
11. Sharma P, Retz M, Siefker-Radtke A, et al. Nivolumab in metastatic urothelial carcinoma after platinum therapy (CheckMate 275): A multicentre, single-arm, phase 2 trial. *Lancet Oncol*. 2017.
12. MICROMEDEX®SOLUTIONS Compendia. 2018. Atezolizumab.
13. MICROMEDEX®SOLUTIONS Compendia. 2018. Avelumab.
14. MICROMEDEX®SOLUTIONS Compendia. 2018. Durvalumab.
15. MICROMEDEX®SOLUTIONS Compendia. 2018. Nivolumab
16. MICROMEDEX®SOLUTIONS Compendia. 2018. Pembrolizumab.
17. Bavencio® (avelumab) [package insert]. EMD Serono, Inc. Rockland, MA. October 2017.

18. Gupta S, Gill D, Poole A, et al. Systemic immunotherapy for urothelial cancer: Current trends and future directions. *Cancers (Basel)*. 2017; 9(2): 15.
19. Imfinzi™ (durvalumab) [package insert]. AstraZeneca Pharmaceuticals LP, Wilmington, DE. February 2018.
20. Villaruz L, Socinski M. The clinical utility of PD-L1 testing in selecting non-small cell lung cancer patients for PD1/PD-L1 directed therapy. *Clin Pharmacol Ther*. 2016; 100(3): 212–214.
21. American Cancer Society (ACS). Key Statistics for Bladder Cancer. January 5, 2017.
22. Tecentriq® (atezolizumab) [package insert]. Genentech, Inc., South San Francisco, CA 94080. December 2018.
23. National Comprehensive Cancer Network (NCCN). NCCN Avelumab. Version 5.2018.
24. Clinical Pharmacology Compendia. 2018 Tampa FL: Gold Standard, Inc. Atezolizumab.
25. Clinical Pharmacology Compendia. 2018 Tampa FL: Gold Standard, Inc. Avelumab.
26. Clinical Pharmacology Compendia. 2018 Tampa FL: Gold Standard, Inc. Durvalumab.
27. Clinical Pharmacology Compendia. 2018 Tampa FL: Gold Standard, Inc. Nivolumab.
28. Clinical Pharmacology Compendia. 2018 Tampa FL: Gold Standard, Inc. Pembrolizumab.
29. Tomasini P, Greillier L, Boyer A, Jeanson A, & Barlesi F. Durvalumab After Chemoradiotherapy in Stage III Non-Small Cell Lung Cancer. *J Thorac Dis*. 2018; 10(9):S1032-S1036.
30. Johnson B & Eng C. The Promise of Immunotherapy in Anal Squamous Cell Carcinoma: A Novel Approach for an Orphan Disease. *Clin Adv Hematol Oncol*. December 2017;15(12):968-978.
31. Kudo M. Immune Checkpoint Inhibition in hepatocellular Carcinoma: Basics and Ongoing Clinical Trials. *Oncology*. 2017;92(suppl 1):50-62.
32. Chan I, Bhatia S, Kaufman H, & Lipson E. Immunotherapy for Merkel Cell Carcinoma: a Turning Point in Patient Care. *J Immunother Cancer Res*. 2018; 6:23.
33. Algazi A, Tsai K, Shoushtari A, et al. Clinical Outcomes in Metastatic Uveal Melanoma Treated with PD-1 and PD-L1 Antibodies. *Cancer*. 2016; 122(21):3344-3353.
34. Le D, Uram J, Wang H, et al. PD-1 Blockade in Tumors with Mismatch-Repair Deficiency. *N Engl J Med*. 2015; 372:2509-2520.
35. Kwong Y, Chan T, Tan D, et al. PD1 Blockade with Pembrolizumab is Highly Effective in Relapsed or Refractory NK/T-cll Lymphoma Failing L-Asparaginase. *Blood*. 2017; 129:2437-2442.

36. Doi T, Piha-Paul S, Jalal S, et al. Safety and Antitumor Activity of the Anti-Programmed Death-1 Antibody Pembrolizumab in Patients with Advanced Esophageal Carcinoma. *J Clin Onco.* 2018;36:61-67.
37. Sharma P, Callahan M, Bono P, et al. Nivolumab monotherapy in metastatic urothelial carcinoma: Longer-term efficacy and safety results from the CheckMate 032 study. *J Clin Onco.* 2018;36(6):414-414.
38. Velde N, Guerin A, Ionescu-Ittu R, et al. Comparative Effectiveness of Non-cisplatin First-line Therapies for Metastatic Urothelial Carcinoma: Phase 2 IMvigor210 Study Versus US Patients Treated in the Veterans Health Administration. *Eur Uro Oncol.* 2018;07:1-9.
39. Garassino M, Rodriguez-Abreu D, Gadgeel S, et al. Health-related quality of life (HRQoL) in the KEYNOTE-189 study of pembrolizumab (pembro) or placebo (pbo) + pemetrexed (pem) + platinum (plt) for metastatic NSCLC. *J Clin Onco.* 2018;36(15):9021-9021.
40. Vuky J, Balar A, Castellano D, et al. Updated efficacy and safety of KEYNOTE-052: A single-arm phase 2 study investigating first-line pembrolizumab (pembro) in cisplatin-ineligible advanced urothelial cancer (UC). *J Clin Oncol.* 2018;36(15):4524.
41. Chung H, Schellens J, Delord J, et al. Pembrolizumab treatment of advanced cervical cancer: Updated results from the phase 2 KEYNOTE-158 study. *J Clin Oncol.* 2018;36(15):5522.
42. Libtayo® (cemiplimab-rwlc) [package insert]. Regeneron Pharmaceuticals, Tarrytown, NY. September 2018.
43. Migden M, Rischin D, Schmults C, et al. PD-1 Blockade with Cemiplimab in Advanced Cutaneous Squamous-Cell Carcinoma. *N Engl J Med.* 2018;379(4):1-10.
44. NCCN Drugs & Biologics Compendium™. Keytruda® (pembrolizumab) Drugs & Biologic Compendium®. Copyright 2019. National Comprehensive Cancer Network (NCCN).
45. NCCN Drugs & Biologics Compendium™. Opdivo® (nivolumab) Drugs & Biologic Compendium®. Copyright 2019. National Comprehensive Cancer Network (NCCN).
46. NCCN Drugs & Biologics Compendium™. Imfinzi® (durvalumab) Drugs & Biologic Compendium®. Copyright 2019. National Comprehensive Cancer Network (NCCN).
47. NCCN Drugs & Biologics Compendium™. Tecentriq® (atezolizumab) Drugs & Biologic Compendium®. Copyright 2019. National Comprehensive Cancer Network (NCCN).